586 related articles for article (PubMed ID: 24449227)
1. Association of peripheral neuropathy with circulating advanced glycation end products, soluble receptor for advanced glycation end products and other risk factors in patients with type 2 diabetes.
Aubert CE; Michel PL; Gillery P; Jaisson S; Fonfrede M; Morel F; Hartemann A; Bourron O
Diabetes Metab Res Rev; 2014 Nov; 30(8):679-85. PubMed ID: 24449227
[TBL] [Abstract][Full Text] [Related]
2. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients.
Kerkeni M; Saïdi A; Bouzidi H; Letaief A; Ben Yahia S; Hammami M
Diab Vasc Dis Res; 2013 May; 10(3):239-45. PubMed ID: 23091285
[TBL] [Abstract][Full Text] [Related]
3. The association between pulse wave velocity and peripheral neuropathy in patients with type 2 diabetes mellitus.
Tentolouris A; Eleftheriadou I; Grigoropoulou P; Kokkinos A; Siasos G; Ntanasis-Stathopoulos I; Tentolouris N
J Diabetes Complications; 2017 Nov; 31(11):1624-1629. PubMed ID: 28893495
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
[TBL] [Abstract][Full Text] [Related]
5. sRAGE and esRAGE are not associated with peripheral or autonomic neuropathy in type 2 diabetes.
Humpert PM; Papadopoulos G; Schaefer K; Djuric Z; Konrade I; Morcos M; Nawroth PP; Bierhaus A
Horm Metab Res; 2007 Dec; 39(12):899-902. PubMed ID: 18046662
[TBL] [Abstract][Full Text] [Related]
6. Association of advanced glycation end products and chronic kidney disease with macroangiopathy in type 2 diabetes.
Rigalleau V; Cougnard-Gregoire A; Nov S; Gonzalez C; Maury E; Lorrain S; Gin H; Barberger-Gateau P
J Diabetes Complications; 2015 Mar; 29(2):270-4. PubMed ID: 25468311
[TBL] [Abstract][Full Text] [Related]
7. Serum soluble receptor for advanced glycation end products correlates inversely with measures of adiposity in young adults.
Davis KE; Prasad C; Vijayagopal P; Juma S; Imrhan V
Nutr Res; 2014 Jun; 34(6):478-85. PubMed ID: 25026914
[TBL] [Abstract][Full Text] [Related]
8. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.
Yamagishi S; Adachi H; Nakamura K; Matsui T; Jinnouchi Y; Takenaka K; Takeuchi M; Enomoto M; Furuki K; Hino A; Shigeto Y; Imaizumi T
Metabolism; 2006 Sep; 55(9):1227-31. PubMed ID: 16919543
[TBL] [Abstract][Full Text] [Related]
9. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes.
Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
Diabetes Metab Res Rev; 2008 Feb; 24(2):109-14. PubMed ID: 17694504
[TBL] [Abstract][Full Text] [Related]
10. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension.
Busch M; Franke S; Wolf G; Brandstädt A; Ott U; Gerth J; Hunsicker LG; Stein G;
Am J Kidney Dis; 2006 Oct; 48(4):571-9. PubMed ID: 16997053
[TBL] [Abstract][Full Text] [Related]
11. Total plasma Nε-(carboxymethyl)lysine and sRAGE levels are inversely associated with a number of metabolic syndrome risk factors in non-diabetic young-to-middle-aged medication-free subjects.
Sebeková K; Krivošíková Z; Gajdoš M
Clin Chem Lab Med; 2014 Jan; 52(1):139-49. PubMed ID: 23509221
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum levels of AGEs, sRAGE, and pentosidine in Tunisian patients with severity of diabetic retinopathy.
Kerkeni M; Saïdi A; Bouzidi H; Ben Yahya S; Hammami M
Microvasc Res; 2012 Nov; 84(3):378-83. PubMed ID: 22835520
[TBL] [Abstract][Full Text] [Related]
13. Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness.
Choi KM; Yoo HJ; Kim HY; Lee KW; Seo JA; Kim SG; Kim NH; Choi DS; Baik SH
Int J Cardiol; 2009 Feb; 132(1):96-101. PubMed ID: 18190981
[TBL] [Abstract][Full Text] [Related]
14. Glycated peptides are associated with the variability of endothelial dysfunction in the cerebral vessels and the kidney in type 2 diabetes mellitus patients: a cross-sectional study.
Petrica L; Vlad A; Gluhovschi G; Gadalean F; Dumitrascu V; Vlad D; Popescu R; Velciov S; Gluhovschi C; Bob F; Ursoniu S; Petrica M; Jianu DC
J Diabetes Complications; 2015 Mar; 29(2):230-7. PubMed ID: 25511877
[TBL] [Abstract][Full Text] [Related]
15. Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function.
Gohda T; Tanimoto M; Moon JY; Gotoh H; Aoki T; Matsumoto M; Shibata T; Ohsawa I; Funabiki K; Tomino Y
Diabetes Res Clin Pract; 2008 Aug; 81(2):196-201. PubMed ID: 18550199
[TBL] [Abstract][Full Text] [Related]
16. Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels.
Gaens KH; Ferreira I; van der Kallen CJ; van Greevenbroek MM; Blaak EE; Feskens EJ; Dekker JM; Nijpels G; Heine RJ; 't Hart LM; de Groot PG; Stehouwer CD; Schalkwijk CG
J Clin Endocrinol Metab; 2009 Dec; 94(12):5174-80. PubMed ID: 19890027
[TBL] [Abstract][Full Text] [Related]
17. Role of advanced glycation end product (AGE)-induced receptor (RAGE) expression in diabetic vascular complications.
Chawla D; Bansal S; Banerjee BD; Madhu SV; Kalra OP; Tripathi AK
Microvasc Res; 2014 Sep; 95():1-6. PubMed ID: 24984291
[TBL] [Abstract][Full Text] [Related]
18. Below-knee arterial calcification in type 2 diabetes: association with receptor activator of nuclear factor κB ligand, osteoprotegerin, and neuropathy.
Bourron O; Aubert CE; Liabeuf S; Cluzel P; Lajat-Kiss F; Dadon M; Komajda M; Mentaverri R; Brazier M; Pierucci A; Morel F; Jacqueminet S; Massy ZA; Hartemann A
J Clin Endocrinol Metab; 2014 Nov; 99(11):4250-8. PubMed ID: 25013993
[TBL] [Abstract][Full Text] [Related]
19. Role of advanced glycation end products and their receptors in development of diabetic neuropathy.
Wada R; Yagihashi S
Ann N Y Acad Sci; 2005 Jun; 1043():598-604. PubMed ID: 16037282
[TBL] [Abstract][Full Text] [Related]
20. The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction.
Willemsen S; Hartog JW; van Veldhuisen DJ; van der Meer P; Roze JF; Jaarsma T; Schalkwijk C; van der Horst IC; Hillege HL; Voors AA
Am Heart J; 2012 Nov; 164(5):742-749.e3. PubMed ID: 23137505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
